MX2017001285A - Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. - Google Patents

Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.

Info

Publication number
MX2017001285A
MX2017001285A MX2017001285A MX2017001285A MX2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A
Authority
MX
Mexico
Prior art keywords
htt
antibodies
human
derived anti
huntingtin
Prior art date
Application number
MX2017001285A
Other languages
English (en)
Inventor
Grimm Jan
Maier Marcel
Original Assignee
Neurimmune Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding Ag filed Critical Neurimmune Holding Ag
Publication of MX2017001285A publication Critical patent/MX2017001285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)

Abstract

Se proporcionan novedosos anticuerpos anti-huntingtina (HTT) derivados de humano y los derivados biotecnológicos de los mismos, de preferencia capaces de enlazarse a las especies mutadas y/o aglomeradas de huntingtina (HTT), y/o los fragmentos de los mismos, así como los métodos relacionados con los mismos. Los anticuerpos anti-huntingtina (HTT) derivados de humano y los derivados biotecnológicos se pueden utilizar en composiciones farmacéuticas y de diagnóstico para la inmunoterapia de la enfermedad de Huntington dirigida a la huntingtina (HTT), y para el diagnóstico de la misma.
MX2017001285A 2014-07-29 2015-07-29 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. MX2017001285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179004 2014-07-29
PCT/EP2015/067327 WO2016016278A2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (htt) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2017001285A true MX2017001285A (es) 2017-04-25

Family

ID=51225442

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017001285A MX2017001285A (es) 2014-07-29 2015-07-29 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX2022003704A MX2022003704A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX2022003706A MX2022003706A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022003704A MX2022003704A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX2022003706A MX2022003706A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.

Country Status (11)

Country Link
US (3) US10556946B2 (es)
EP (1) EP3174898A2 (es)
JP (3) JP2017522886A (es)
KR (1) KR102643395B1 (es)
CN (2) CN107074937B (es)
AU (3) AU2015295441B2 (es)
CA (1) CA2954738A1 (es)
EA (1) EA201790165A1 (es)
IL (2) IL250180A0 (es)
MX (3) MX2017001285A (es)
WO (1) WO2016016278A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
MX2017001285A (es) * 2014-07-29 2017-04-25 Neurimmune Holding Ag Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2020001855A (es) 2017-08-22 2020-08-13 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
CN111909265B (zh) * 2020-08-25 2022-02-11 中国人民解放军军事科学院军事医学研究院 一种结合破伤风毒素重链c端结构域的人源抗体及应用
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
WO2024121347A1 (en) * 2022-12-07 2024-06-13 Alchemab Therapeutics Ltd Anti-huntingtin antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116280A1 (en) 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
WO1999006838A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel method of detecting amyloid-like fibrils or protein aggregates
AU2002250102B2 (en) * 2001-02-15 2007-07-12 University Of Chicago Yeast screens for agents affecting protein folding
US7375194B2 (en) * 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
JP4179562B2 (ja) * 2003-05-14 2008-11-12 独立行政法人科学技術振興機構 ハンチンチン遺伝子の発現抑制
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
CN101622275B (zh) 2007-01-05 2013-11-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
WO2013013025A2 (en) * 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
AU2014272024B2 (en) * 2013-05-29 2018-03-15 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
ES2660372T3 (es) * 2014-07-10 2018-03-22 Affiris Ag Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington
CA2954687A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
MX2017001285A (es) * 2014-07-29 2017-04-25 Neurimmune Holding Ag Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.

Also Published As

Publication number Publication date
JP2023052519A (ja) 2023-04-11
KR20170036785A (ko) 2017-04-03
US10556946B2 (en) 2020-02-11
AU2020217427A1 (en) 2020-09-03
IL250180A0 (en) 2017-03-30
MX2022003704A (es) 2022-04-26
CA2954738A1 (en) 2016-02-04
CN107074937B (zh) 2021-07-27
US20220332808A1 (en) 2022-10-20
US20200392217A1 (en) 2020-12-17
CN107074937A (zh) 2017-08-18
US20170166631A1 (en) 2017-06-15
JP7235939B2 (ja) 2023-03-09
IL276721A (en) 2020-09-30
MX2022003706A (es) 2022-04-26
WO2016016278A3 (en) 2016-03-24
AU2024200315A1 (en) 2024-02-08
US11401325B2 (en) 2022-08-02
AU2015295441B2 (en) 2020-05-14
JP2021003100A (ja) 2021-01-14
EA201790165A1 (ru) 2017-07-31
KR102643395B1 (ko) 2024-03-11
AU2015295441A1 (en) 2017-02-02
JP2017522886A (ja) 2017-08-17
EP3174898A2 (en) 2017-06-07
WO2016016278A2 (en) 2016-02-04
AU2020217427B2 (en) 2023-10-19
CN113651887A (zh) 2021-11-16
NZ728372A (en) 2021-11-26

Similar Documents

Publication Publication Date Title
MX2022003704A (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12016501366A1 (en) Novel anti-baff antibodies
IL287607A (en) Preparations, kits and methods for inducing acquired cellular resistance using inducible stress proteins
PH12017500489A1 (en) Human-derived anti-dipeptide repeats (dprs) antibody
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
GB2541150A (en) Improvements in and relating to sample collection
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2017008096A (es) Pestivirus.
MX2016013584A (es) Parvovirus porcino.
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2016012986A (es) Composiciones y metodos para identificar especies de ehrlichia.
EP3096136A4 (en) Composition, method for preparing sugar chain sample, and method for analyzing sugar chain
EP4328245A3 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP3135763A4 (en) Method for improving protein expression, and composition for protein expression
AU2021236446A1 (en) CRISPR-Cas-related methods, compositions and components for cancer immunotherapy